Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 7/20 | 0.49 |
| ▸ | MARK3 | P27448 | 5/20 | 0.47 |
| ▸ | MARK4 | Q96L34 | 4/20 | 0.47 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.45 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.45 |
| ▸ | STK4 | Q13043 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400703 | 0.88 | PLK1 (0.51) | PLK1MARK3MARK4STK4BRD4 | |
| SCHEMBL2396937 | 0.86 | MARK3 (0.59) | PLK1MARK3MARK4PLK3PLK2 | |
| SCHEMBL2395765 | 0.86 | PLK1 (0.52) | PLK1MARK3MARK4BRD4MAPK7 | |
| SCHEMBL9945383 | 0.85 | PLK1 (0.53) | PLK1MARK3MARK4BRD4MAPK7 | |
| SCHEMBL2396655 | 0.85 | PIK3CA (0.50) | PLK1MARK3MARK4STK4BRD4 | |
| SCHEMBL2399376 | 0.84 | PLK1 (0.51) | PLK1MARK3MARK4BRD4MAPK7 | |
| SCHEMBL2397220 | 0.84 | MARK3 (0.50) | PLK1MARK3MARK4BRD4MAPK7 | |
| SCHEMBL2395421 | 0.84 | PLK1 (0.55) | PLK1MARK3MARK4BRD4MAPK7 | |
| SCHEMBL2396972 | 0.83 | PLK1 (0.54) | PLK1PLK3PLK2BRD4BRDT | |
| SCHEMBL2399054 | 0.83 | PLK1 (0.51) | PLK1MARK3MARK4BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480550-B1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-8394952-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394952-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394952-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120271045-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120271045-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120149898-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100190765-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190765-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7622463-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622463-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622463-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1983987-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120271045-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | DCK, MAP3K5, MAP3K1 | PLK1 42/4885MARK3 378/4885MARK4 336/4885 |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP4K2 | PLK1 89/4885MARK3 123/4885MARK4 133/4885 |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K5, MAP4K2 | PLK1 89/4885MARK3 123/4885MARK4 133/4885 |
| US-20120149898-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K5, MAP4K2 | PLK1 89/4885MARK3 123/4885MARK4 133/4885 |
| US-20100190765-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K5, MAP4K2 | PLK1 89/4885MARK3 123/4885MARK4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.